SCHOTT Pharma KGaA（1SXP）株式概要SCHOTT Pharma AG & Co.KGaAは、世界中の製薬、バイオテクノロジー、ライフサイエンス業界向けに、薬剤封じ込めソリューションと注射薬送達システムを開発、製造、販売しています。 詳細1SXP ファンダメンタル分析スノーフレーク・スコア評価5/6将来の成長1/6過去の実績2/6財務の健全性6/6配当金2/6報酬当社が推定した公正価値より29.7%で取引されている 収益は年間9.41%増加すると予測されています 同業他社や業界と比較して、良好な取引価格 リスク分析リスクチェックの結果、1SXP 、リスクは検出されなかった。すべてのリスクチェックを見る1SXP Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€16.925.5% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture01b2016201920222025202620282031Revenue €1.3bEarnings €191.9mAdvancedSet Fair ValueView all narrativesSCHOTT Pharma AG & Co. KGaA 競合他社GerresheimerSymbol: XTRA:GXIMarket cap: €945.7mSartoriusSymbol: XTRA:SRT3Market cap: €14.3bDermapharm HoldingSymbol: XTRA:DMPMarket cap: €2.4bAddLifeSymbol: OM:ALIF BMarket cap: SEK 18.5b価格と性能株価の高値、安値、推移の概要SCHOTT Pharma KGaA過去の株価現在の株価€16.9252週高値€30.1052週安値€12.68ベータ0.891ヶ月の変化12.80%3ヶ月変化13.56%1年変化-41.25%3年間の変化n/a5年間の変化n/aIPOからの変化-45.84%最新ニュースお知らせ • Feb 05Schott Pharma Ag & Co. Kgaa Approves DividendSCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income.Price Target Changed • Jan 12Price target decreased by 9.8% to €20.72Down from €22.97, the current price target is an average from 12 analysts. New target price is 32% above last closing price of €15.70. Stock is down 38% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.Price Target Changed • Dec 30Price target decreased by 20% to €22.97Down from €28.60, the current price target is an average from 13 analysts. New target price is 54% above last closing price of €14.94. Stock is down 40% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.Declared Dividend • Dec 30Dividend increased to €0.18Dividend of €0.18 is 13% higher than last year. Ex-date: 4th February 2026 Payment date: 6th February 2026 Dividend yield will be 1.2%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by both earnings (19% earnings payout ratio) and cash flows (77% cash payout ratio). The dividend has increased by an average of 9.5% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Dec 22SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026, at 10:00 W. Europe Standard Time.お知らせ • Dec 12SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026.最新情報をもっと見るRecent updatesお知らせ • Feb 05Schott Pharma Ag & Co. Kgaa Approves DividendSCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income.Price Target Changed • Jan 12Price target decreased by 9.8% to €20.72Down from €22.97, the current price target is an average from 12 analysts. New target price is 32% above last closing price of €15.70. Stock is down 38% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.Price Target Changed • Dec 30Price target decreased by 20% to €22.97Down from €28.60, the current price target is an average from 13 analysts. New target price is 54% above last closing price of €14.94. Stock is down 40% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.Declared Dividend • Dec 30Dividend increased to €0.18Dividend of €0.18 is 13% higher than last year. Ex-date: 4th February 2026 Payment date: 6th February 2026 Dividend yield will be 1.2%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by both earnings (19% earnings payout ratio) and cash flows (77% cash payout ratio). The dividend has increased by an average of 9.5% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Dec 22SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026, at 10:00 W. Europe Standard Time.お知らせ • Dec 12SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026.お知らせ • Dec 06SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 04, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results at 5:30 PM, Central European Standard Time on Dec 04, 2025お知らせ • Oct 09SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2026 Results on Dec 10, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2026 results on Dec 10, 2026お知らせ • Aug 19+ 2 more updatesSCHOTT Pharma AG & Co. KGaA to Report Q3, 2026 Results on Aug 12, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report Q3, 2026 results on Aug 12, 2026お知らせ • Jun 13SCHOTT Pharma Management AG Announces CFO ChangesThe Supervisory Board of SCHOTT Pharma Management AG has decided that CFO Dr. Almuth Steinkühler informed the Supervisory Board that she does not seek another term in office. She will leave SCHOTT Pharma at her own request after her current contract expires on July 31, 2025, to pursue new professional challenges. Reinhard Mayer will succeed Dr. Almuth Steinkühler on August 1, 2025. A graduate in industrial engineering, he looks back on many years of experience in corporate finance, controlling, and IT, including over 20 years in CFO positions. Mayer brings a wealth of perspectives from leading diverse global teams in multinational, publicly traded companies. In his most recent position as CFO of Denmark-listed Nilfisk Holding A/S, Mayer played a key role in shaping the company’s strategy for organic growth, overseeing financial consolidation and optimizing and digitizing business processes. Before that, he served as CFO on the Executive Board of Hansgrohe SE and spent 15 years in various global management positions, most recently as CFO at the Getinge Group, a publicly listed medical technology group based in Sweden.お知らせ • Dec 19SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 04, 2025SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 04, 2025, at 10:00 W. Europe Standard Time.お知らせ • Nov 16+ 3 more updatesSCHOTT Pharma AG & Co. KGaA to Report First Half, 2025 Results on May 15, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report first half, 2025 results on May 15, 2025お知らせ • Sep 05SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2024 Results on Dec 12, 2024SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2024 results on Dec 12, 2024Reported Earnings • Aug 30Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: €0.31 (up from €0.20 in 3Q 2023). Revenue: €253.6m (up 15% from 3Q 2023). Net income: €46.3m (up 52% from 3Q 2023). Profit margin: 18% (up from 14% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) also surpassed analyst estimates by 52%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €36.18, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 22x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €46.51 per share.Reported Earnings • Jun 28Second quarter 2024 earnings: EPS misses analyst expectationsSecond quarter 2024 results: EPS: €0.17. Net income: €25.0m (up €25.0m from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €31.78, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 22x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €47.63 per share.Reported Earnings • Mar 03First quarter 2024 earnings released: EPS: €0.29 (vs €0.17 in 1Q 2023)First quarter 2024 results: EPS: €0.29 (up from €0.17 in 1Q 2023). Revenue: €232.3m (up 14% from 1Q 2023). Net income: €44.4m (up 74% from 1Q 2023). Profit margin: 19% (up from 13% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.Buy Or Sell Opportunity • Feb 29Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 45% to €42.60. The fair value is estimated to be €35.03, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.お知らせ • Feb 27+ 1 more updateSCHOTT Pharma AG & Co. KGaA to Report First Half, 2024 Results on Feb 29, 2024SCHOTT Pharma AG & Co. KGaA announced that they will report first half, 2024 results on Feb 29, 2024Buy Or Sell Opportunity • Feb 01Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 30% to €36.80. The fair value is estimated to be €30.65, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.お知らせ • Sep 29SCHOTT Pharma AG & Co. KGaA has completed an IPO in the amount of €813.318959 million.SCHOTT Pharma AG & Co. KGaA has completed an IPO in the amount of €813.318959 million. Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 7,407,407 Price\Range: €27 Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 22,715,517 Price\Range: €27 Transaction Features: Regulation S; Rule 144A株主還元1SXPDE Life SciencesDE 市場7D3.4%6.3%2.8%1Y-41.3%-12.2%1.4%株主還元を見る業界別リターン: 1SXP過去 1 年間で-12.2 % の収益を上げたGerman Life Sciences業界を下回りました。リターン対市場: 1SXPは、過去 1 年間で1.4 % のリターンを上げたGerman市場を下回りました。価格変動Is 1SXP's price volatile compared to industry and market?1SXP volatility1SXP Average Weekly Movement4.6%Life Sciences Industry Average Movement9.1%Market Average Movement6.0%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.7%安定した株価: 1SXP 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 1SXPの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト18844,839Christian Miaswww.schott-pharma.comSCHOTT Pharma AG & Co KGaAは、世界中の製薬、バイオテクノロジー、ライフサイエンス業界向けに、薬剤封入ソリューションおよび注射薬デリバリーシステムを開発、製造、販売しています。同社は、プレフィラブルガラスまたはポリマーシリンジ、ガラスバイアル、カートリッジ、アンプルを提供している。シリンジ製品には、ワクチン用ガラスシリンジ「syriQ」、生物製剤用ガラスシリンジ「syriQ BioPure」、プレフィラブルでシリコーンフリーの生物製剤用ガラスシリンジ「syriQ BioPure silicone-free」、ポリマーシリンジ「SCHOTT TOPPAC」、美容治療用ポリマーシリンジ「SCHOTT TOPPAC cosmetic」などがある；深冷用ポリマーシリンジ「SCHOTT TOPPAC freeze」、高感度薬剤用ポリマーシリンジ「SCHOTT TOPPAC sensitive」、輸液療法用ポリマーシリンジ「SCHOTT TOPPAC infuse」、ポリマー容器「SCHOTT TOPPAC unique」。また、ペプチドおよびタンパク質ベースの注射剤用医薬用ガラスカートリッジ「cartriQ」、大容量注射剤用医薬用ガラスカートリッジ「cartriQ Large Volume」、凍結乾燥薬剤用医薬用ガラスカートリッジ「Cartridges Double Chamber」、医薬用ガラスカートリッジ「Cartridges Break Resistant」、TopLineおよびStandardLineカートリッジなどの製品も提供している。さらに、注射剤用医薬ガラスバイアル「adaptiQ」、比類のない薬物安定性用医薬ガラスバイアル「EVERIC pure」、pH範囲用医薬ガラスバイアル「EVERIC care」、充填ライン性能用医薬ガラスバイアル「EVERIC strong & smooth」、製剤用医薬ガラスバイアル「SCHOTT Type I plus」、凍結乾燥薬物用曇り防止用医薬ガラスバイアル「SCHOTT TopLyo」、TopLineおよびStandardLineバイアルを提供している。さらに、アンプル製品として、アンプル開封用医薬用ガラスアンプルAmpoules easyOPC、医薬品偽造防止用医薬用ガラスアンプルAmpoules Anti-Counterfeiting、StandardLineアンプルなどを提供している。同社は1884年に設立され、ドイツのマインツに本社を置いています。SCHOTT Pharma AG & Co KGaAはSchott Glaswerke Beteiligungs- Und Export Gmbhの子会社として運営されています。もっと見るSCHOTT Pharma AG & Co. KGaA 基礎のまとめSCHOTT Pharma KGaA の収益と売上を時価総額と比較するとどうか。1SXP 基礎統計学時価総額€2.58b収益（TTM）€142.82m売上高(TTM)€991.22m18.0xPER（株価収益率2.6xP/Sレシオ1SXP は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計1SXP 損益計算書（TTM）収益€991.22m売上原価€664.75m売上総利益€326.47mその他の費用€183.65m収益€142.82m直近の収益報告Mar 31, 2026次回決算日Aug 12, 2026一株当たり利益（EPS）0.95グロス・マージン32.94%純利益率14.41%有利子負債／自己資本比率23.7%1SXP の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.1%現在の配当利回り19%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 08:10終値2026/05/26 00:00収益2026/03/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SCHOTT Pharma AG & Co. KGaA 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。23 アナリスト機関Gaurav JainBarclaysPallav MittalBarclaysJonathon UnwinBarclays20 その他のアナリストを表示
お知らせ • Feb 05Schott Pharma Ag & Co. Kgaa Approves DividendSCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income.
Price Target Changed • Jan 12Price target decreased by 9.8% to €20.72Down from €22.97, the current price target is an average from 12 analysts. New target price is 32% above last closing price of €15.70. Stock is down 38% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.
Price Target Changed • Dec 30Price target decreased by 20% to €22.97Down from €28.60, the current price target is an average from 13 analysts. New target price is 54% above last closing price of €14.94. Stock is down 40% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.
Declared Dividend • Dec 30Dividend increased to €0.18Dividend of €0.18 is 13% higher than last year. Ex-date: 4th February 2026 Payment date: 6th February 2026 Dividend yield will be 1.2%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by both earnings (19% earnings payout ratio) and cash flows (77% cash payout ratio). The dividend has increased by an average of 9.5% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Dec 22SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026, at 10:00 W. Europe Standard Time.
お知らせ • Dec 12SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026.
お知らせ • Feb 05Schott Pharma Ag & Co. Kgaa Approves DividendSCHOTT Pharma AG & Co. KGaA announced that at the Annual General Meeting held on February 3, 2026, approved the proposed dividend of EUR 0.18 per share, which corresponds to a payout ratio of 18% of consolidated net income.
Price Target Changed • Jan 12Price target decreased by 9.8% to €20.72Down from €22.97, the current price target is an average from 12 analysts. New target price is 32% above last closing price of €15.70. Stock is down 38% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.
Price Target Changed • Dec 30Price target decreased by 20% to €22.97Down from €28.60, the current price target is an average from 13 analysts. New target price is 54% above last closing price of €14.94. Stock is down 40% over the past year. The company is forecast to post earnings per share of €0.95 for next year compared to €0.97 last year.
Declared Dividend • Dec 30Dividend increased to €0.18Dividend of €0.18 is 13% higher than last year. Ex-date: 4th February 2026 Payment date: 6th February 2026 Dividend yield will be 1.2%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by both earnings (19% earnings payout ratio) and cash flows (77% cash payout ratio). The dividend has increased by an average of 9.5% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Dec 22SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 03, 2026, at 10:00 W. Europe Standard Time.
お知らせ • Dec 12SCHOTT Pharma AG & Co. KGaA announces Annual dividend, payable on February 06, 2026SCHOTT Pharma AG & Co. KGaA announced Annual dividend of EUR 0.1800 per share payable on February 06, 2026, ex-date on February 04, 2026 and record date on February 05, 2026.
お知らせ • Dec 06SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2025 Results on Dec 04, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2025 results at 5:30 PM, Central European Standard Time on Dec 04, 2025
お知らせ • Oct 09SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2026 Results on Dec 10, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2026 results on Dec 10, 2026
お知らせ • Aug 19+ 2 more updatesSCHOTT Pharma AG & Co. KGaA to Report Q3, 2026 Results on Aug 12, 2026SCHOTT Pharma AG & Co. KGaA announced that they will report Q3, 2026 results on Aug 12, 2026
お知らせ • Jun 13SCHOTT Pharma Management AG Announces CFO ChangesThe Supervisory Board of SCHOTT Pharma Management AG has decided that CFO Dr. Almuth Steinkühler informed the Supervisory Board that she does not seek another term in office. She will leave SCHOTT Pharma at her own request after her current contract expires on July 31, 2025, to pursue new professional challenges. Reinhard Mayer will succeed Dr. Almuth Steinkühler on August 1, 2025. A graduate in industrial engineering, he looks back on many years of experience in corporate finance, controlling, and IT, including over 20 years in CFO positions. Mayer brings a wealth of perspectives from leading diverse global teams in multinational, publicly traded companies. In his most recent position as CFO of Denmark-listed Nilfisk Holding A/S, Mayer played a key role in shaping the company’s strategy for organic growth, overseeing financial consolidation and optimizing and digitizing business processes. Before that, he served as CFO on the Executive Board of Hansgrohe SE and spent 15 years in various global management positions, most recently as CFO at the Getinge Group, a publicly listed medical technology group based in Sweden.
お知らせ • Dec 19SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 04, 2025SCHOTT Pharma AG & Co. KGaA, Annual General Meeting, Feb 04, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Nov 16+ 3 more updatesSCHOTT Pharma AG & Co. KGaA to Report First Half, 2025 Results on May 15, 2025SCHOTT Pharma AG & Co. KGaA announced that they will report first half, 2025 results on May 15, 2025
お知らせ • Sep 05SCHOTT Pharma AG & Co. KGaA to Report Fiscal Year 2024 Results on Dec 12, 2024SCHOTT Pharma AG & Co. KGaA announced that they will report fiscal year 2024 results on Dec 12, 2024
Reported Earnings • Aug 30Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: €0.31 (up from €0.20 in 3Q 2023). Revenue: €253.6m (up 15% from 3Q 2023). Net income: €46.3m (up 52% from 3Q 2023). Profit margin: 18% (up from 14% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) also surpassed analyst estimates by 52%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €36.18, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 22x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €46.51 per share.
Reported Earnings • Jun 28Second quarter 2024 earnings: EPS misses analyst expectationsSecond quarter 2024 results: EPS: €0.17. Net income: €25.0m (up €25.0m from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €31.78, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 22x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €47.63 per share.
Reported Earnings • Mar 03First quarter 2024 earnings released: EPS: €0.29 (vs €0.17 in 1Q 2023)First quarter 2024 results: EPS: €0.29 (up from €0.17 in 1Q 2023). Revenue: €232.3m (up 14% from 1Q 2023). Net income: €44.4m (up 74% from 1Q 2023). Profit margin: 19% (up from 13% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
Buy Or Sell Opportunity • Feb 29Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 45% to €42.60. The fair value is estimated to be €35.03, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
お知らせ • Feb 27+ 1 more updateSCHOTT Pharma AG & Co. KGaA to Report First Half, 2024 Results on Feb 29, 2024SCHOTT Pharma AG & Co. KGaA announced that they will report first half, 2024 results on Feb 29, 2024
Buy Or Sell Opportunity • Feb 01Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 30% to €36.80. The fair value is estimated to be €30.65, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
お知らせ • Sep 29SCHOTT Pharma AG & Co. KGaA has completed an IPO in the amount of €813.318959 million.SCHOTT Pharma AG & Co. KGaA has completed an IPO in the amount of €813.318959 million. Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 7,407,407 Price\Range: €27 Security Name: Ordinary Bearer Shares Security Type: Common Stock Securities Offered: 22,715,517 Price\Range: €27 Transaction Features: Regulation S; Rule 144A
